622 related articles for article (PubMed ID: 20182024)
1. Effects of caffeine in Parkinson's disease: from neuroprotection to the management of motor and non-motor symptoms.
Prediger RD
J Alzheimers Dis; 2010; 20 Suppl 1():S205-20. PubMed ID: 20182024
[TBL] [Abstract][Full Text] [Related]
2. Novel neuroprotection by caffeine and adenosine A(2A) receptor antagonists in animal models of Parkinson's disease.
Kalda A; Yu L; Oztas E; Chen JF
J Neurol Sci; 2006 Oct; 248(1-2):9-15. PubMed ID: 16806272
[TBL] [Abstract][Full Text] [Related]
3. Anxiety in Parkinson's disease: a critical review of experimental and clinical studies.
Prediger RD; Matheus FC; Schwarzbold ML; Lima MM; Vital MA
Neuropharmacology; 2012 Jan; 62(1):115-24. PubMed ID: 21903105
[TBL] [Abstract][Full Text] [Related]
4. The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease.
Prediger RD; Aguiar AS; Moreira EL; Matheus FC; Castro AA; Walz R; De Bem AF; Latini A; Tasca CI; Farina M; Raisman-Vozari R
Curr Pharm Des; 2011; 17(5):489-507. PubMed ID: 21375482
[TBL] [Abstract][Full Text] [Related]
5. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
During MJ; Kaplitt MG; Stern MB; Eidelberg D
Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease.
Xu K; Bastia E; Schwarzschild M
Pharmacol Ther; 2005 Mar; 105(3):267-310. PubMed ID: 15737407
[TBL] [Abstract][Full Text] [Related]
7. A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.
Pinna A; Tronci E; Schintu N; Simola N; Volpini R; Pontis S; Cristalli G; Morelli M
Neuropharmacology; 2010 Mar; 58(3):613-23. PubMed ID: 19951715
[TBL] [Abstract][Full Text] [Related]
8. Non-motor extranigral signs and symptoms in Parkinson's disease.
Wolters ECh
Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S6-12. PubMed ID: 20083010
[TBL] [Abstract][Full Text] [Related]
9. Parkinson's at risk syndrome: can Parkinson's disease be predicted?
Stern MB; Siderowf A
Mov Disord; 2010; 25 Suppl 1():S89-93. PubMed ID: 20187248
[TBL] [Abstract][Full Text] [Related]
10. Non-motor features of Parkinson's disease: depression and dementia.
Reichmann H; Schneider C; Löhle M
Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S87-92. PubMed ID: 20083017
[TBL] [Abstract][Full Text] [Related]
11. Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications.
Morelli M; Di Paolo T; Wardas J; Calon F; Xiao D; Schwarzschild MA
Prog Neurobiol; 2007 Dec; 83(5):293-309. PubMed ID: 17826884
[TBL] [Abstract][Full Text] [Related]
12. Adenosine A2A receptors and Parkinson's disease.
Morelli M; Carta AR; Jenner P
Handb Exp Pharmacol; 2009; (193):589-615. PubMed ID: 19639294
[TBL] [Abstract][Full Text] [Related]
13. Non-motor dysfunction in Parkinson's disease.
Ziemssen T; Reichmann H
Parkinsonism Relat Disord; 2007 Aug; 13(6):323-32. PubMed ID: 17349813
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
15. Norepinephrine: The redheaded stepchild of Parkinson's disease.
Rommelfanger KS; Weinshenker D
Biochem Pharmacol; 2007 Jul; 74(2):177-90. PubMed ID: 17416354
[TBL] [Abstract][Full Text] [Related]
16. Striatal metabotropic glutamate receptors as a target for pharmacotherapy in Parkinson's disease.
Bonsi P; Cuomo D; Picconi B; Sciamanna G; Tscherter A; Tolu M; Bernardi G; Calabresi P; Pisani A
Amino Acids; 2007 Feb; 32(2):189-95. PubMed ID: 16715415
[TBL] [Abstract][Full Text] [Related]
17. Impacts of methylxanthines and adenosine receptors on neurodegeneration: human and experimental studies.
Chen JF; Chern Y
Handb Exp Pharmacol; 2011; (200):267-310. PubMed ID: 20859800
[TBL] [Abstract][Full Text] [Related]
18. Olfactory dysfunction as a diagnostic marker for Parkinson's disease.
Haehner A; Hummel T; Reichmann H
Expert Rev Neurother; 2009 Dec; 9(12):1773-9. PubMed ID: 19951136
[TBL] [Abstract][Full Text] [Related]
19. Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson's disease.
Pinna A; Pontis S; Borsini F; Morelli M
Synapse; 2007 Aug; 61(8):606-14. PubMed ID: 17476684
[TBL] [Abstract][Full Text] [Related]
20. Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson's disease.
Ross GW; Petrovitch H
Drugs Aging; 2001; 18(11):797-806. PubMed ID: 11772120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
